Thank you for your partnership in the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) Program. This program aims to advance our understanding of key disease pathways using new tools to map in three dimensions how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury in rheumatoid arthritis, Sjögren’s disease, lupus, and psoriatic spectrum diseases.
The program will be publicly announced at 9 am ET on December 9, 2021. Please do not share content about the initiative on social media or other channels until that time.
This social media toolkit provides suggested pre-scripted social media posts that your organization can leverage as appropriate to promote the project announcement on Twitter, LinkedIn and Facebook. A social media graphic is also provided and sized for use on these channels.
Please follow the FNIH online on the following social channels and look for the promotion of AMP AIM. Feel free to share, like and comment on the posts.
- Twitter: @FNIH_Org
- Facebook: Facebook.com/FNIHorg
- LinkedIn: Linkedin.com/company/foundation-for-the-national-institutes-of-health
SOCIAL MEDIA POSTS
The linked social media posts feature recommended text, images and links to support the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases program’s announcement. Please feel free to edit the language as appropriate.
Social Media Graphics
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.